TARDBP — TAR DNA Binding Protein 43

📖 Wiki Page

gene1363 wordssynced 2026-04-02

TARDBP (TDP-43)

...

TARDBP (TDP-43)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TARDBP — TAR DNA Binding Protein 43</th>
</tr>
<tr>
<td class="label">TDP-43 Pathology</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Motor neurons</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">Frontal cortex</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>TDP-43 Pathology</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label">FTD (FTLD-TDP)</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label"> Limbic-Predominant AD</td>
<td>Limbic TDP-43 inclusions</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Pathological marker, inclusion formation</td>
</tr>
<tr>
<td class="label">Ubiquitination</td>
<td>Targeting for degradation</td>
</tr>
<tr>
<td class="label">Acetylation</td>
<td>Reduced RNA binding</td>
</tr>
<tr>
<td class="label">Cleavage (C-terminal fragments)</td>
<td>Enhanced aggregation</td>
</tr>
<tr>
<td class="label">Aggregation</td>
<td>Loss of nuclear function</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4fabd9ce" style="color:#ce93d8" title="Score: 0.46">Cryptic Exon Silencing Restoration...</a><br><a href="/hypothesis/h-eea667a9" style="color:#ce93d8" title="Score: 0.45">Cross-Seeding Prevention Strategy...</a><br><a href="/hypothesis/h-7693c291" style="color:#ce93d8" title="Score: 0.44">RNA-Binding Competition Therapy for TDP-...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">670 edges</a></td>
</tr>
</table>

Overview

TARDBP encodes TDP-43, a ubiquitously expressed RNA/DNA-binding protein that is central to RNA processing and stress adaptation in neurons. Pathogenic TARDBP variation and TDP-43 mislocalization are core molecular events in amyotrophic lateral sclerosis, frontotemporal dementia, and mixed ALS-FTD phenotypes.[@neumann2006][@sreedharan2008][@ling2013] Outside inherited disease, TDP-43 pathology is also common in limbic-predominant age-related TDP-43 encephalopathy and is frequently co-detected in Alzheimer's disease, where it worsens cognition and network vulnerability.[@nelson2019][@josephs2014]

Gene And Protein Architecture

TARDBP is located on chromosome 1p36 and encodes a 414-amino-acid hnRNP-family protein with modular domains that map directly to disease biology:[@sreedharan2008][@buratti2008]

N-terminal domain: supports dimerization and assembly into physiological ribonucleoprotein complexes.
Two RNA recognition motifs (RRM1/RRM2): bind UG-rich RNA and selected DNA elements, shaping splicing and transcript stability.
C-terminal low-complexity glycine-rich domain: mediates protein-protein interactions and stress-granule dynamics; this region contains many ALS-linked variants and aggregation-prone motifs.

In healthy neurons, TDP-43 shuttles between nucleus and cytoplasm using nuclear localization and export signals. Disease-associated states feature nuclear depletion with cytoplasmic accumulation, phosphorylation, ubiquitination, and C-terminal fragmentation.[@neumann2006][@ling2013][@mackenzie2010]

Core Biological Functions

RNA Splicing And Transcriptome Integrity

TDP-43 represses cryptic exons and stabilizes long neuronal transcripts; loss of nuclear TDP-43 results in widespread missplicing, including events that impair synaptic and cytoskeletal programs.[@polymenidou2011][@tollervey2011] These transcriptome disruptions are especially damaging in corticospinal and frontotemporal networks where long, highly connected projection neurons depend on tight RNA quality control.

RNA Transport, Translation, And Stress Response

TDP-43 participates in messenger RNP trafficking and stress granule remodeling. Under chronic stress, persistent granules can become nucleation sites for pathological assemblies, linking physiological stress signaling to irreversible proteinopathy.[@ling2013][@ramaswami2013]

DNA Damage And Mitochondrial Coupling

Emerging evidence places TDP-43 at the interface of RNA metabolism and DNA damage response pathways. Cytoplasmic TDP-43 burden correlates with impaired repair programs, while mitochondrial localization changes can amplify oxidative and bioenergetic stress in vulnerable neurons.[@mitra2019][@wang2013]

Disease Associations

ALS Spectrum

Heterozygous TARDBP mutations are established causes of familial and sporadic ALS, often with adult onset and variable upper/lower motor neuron burden.[@sreedharan2008][@kenna2016] At the pathology level, >95% of ALS cases show TDP-43 inclusions even without TARDBP mutation, making TDP-43 a pathway-level convergence node rather than a rare monogenic mechanism.[@neumann2006][@ling2013]

Mechanistically, three coupled processes dominate:

Loss-of-function: nuclear depletion impairs cryptic exon repression and transcript maintenance.

Gain-of-toxic-function: cytoplasmic aggregates and fragments perturb proteostasis and ribostasis.

Network amplification: glial dysfunction and neuroinflammation exacerbate neuronal stress and spread vulnerability.[@ling2013][@ramaswami2013]

Frontotemporal Dementia And ALS-FTD

TARDBP variants and TDP-43 pathology are strongly linked to behavioral variant FTD and ALS-FTD overlap syndromes, where executive, language, and social-cognitive circuits are progressively impaired.[@mackenzie2010][@mackenzie2018] Pathological subtype heterogeneity (FTLD-TDP types A-D) reflects different anatomical and molecular trajectories, but all share TDP-43-centered proteostasis failure.[@mackenzie2018]

Alzheimer Co-Pathology And LATE

In older adults, limbic TDP-43 pathology is common and associated with accelerated memory decline independent of amyloid/tau burden. This supports a multi-proteinopathy model in which TDP-43 acts as a disease modifier that shifts clinical trajectory and therapeutic response windows.[@nelson2019][@josephs2014]

Biomarker And Translational Relevance

TDP-43 currently lacks a single validated clinical assay equivalent to amyloid PET, but multi-modal biomarker approaches are progressing:[@josephs2014][@benatar2018]

Fluid panels: neurofilament light plus inflammatory and RNA-processing markers can enrich for TDP-43 biology.
Genetic context: TARDBP variant carriers may define biologically coherent trial subgroups.
Pathology-informed phenotyping: integrating cognitive-behavioral signatures with motor progression improves case stratification.

For NeuroWiki mechanistic workflows, TARDBP functions as a bridge between RNA metabolism, stress granule pathology, and neuroinflammation.

Therapeutic Strategies

Direct TDP-43 Targeting

Preclinical pipelines include antisense oligonucleotides, RNA-binding modifiers, and approaches that reduce aggregation-prone C-terminal interactions. The dominant challenge is lowering toxic species while preserving essential nuclear function.[@ling2013][@brown2017]

Proteostasis And Autophagy Modulation

Because misfolded TDP-43 burden is partly clearance-limited, therapeutic interest remains high for proteasome/autophagy enhancers and integrated stress response modulators, especially in combination regimens that also reduce neuroinflammatory amplification.[@ramaswami2013][@brown2017]

Trial Design Implications

High heterogeneity in progression and pathology means TARDBP-linked interventions likely need enrichment designs (genotype, progression slope, or molecular endophenotype) rather than broad unselected cohorts.[@kenna2016][@benatar2018]

Research Gaps

Quantitative, longitudinal in vivo markers of TDP-43 burden are still inadequate for rapid phase-2 go/no-go decisions.
The threshold at which adaptive stress granules convert into irreversible aggregates remains unclear in humans.
Interactions between TDP-43 and tau/amyloid axes require better causal modeling in mixed-pathology dementia cohorts.

External Links

[TARDBP Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/23435)
[TDP-43 in ALS - PubMed](https://pubmed.ncbi.nlm.nih.gov/18669820/)
[ALS Association](https://www.als.org/)

Brain Atlas Resources

Expression data and brain atlas resources for TARDBP (TDP-43):

[Allen Human Brain Atlas - TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP): Gene expression data across human brain regions
[Allen Cell Type Atlas - TARDBP](https://portal.brain-map.org/experimental-transcriptomics/?compareHome=true&searchKeyword=TARDBP): Single-cell expression data
[Allen Mouse Brain Atlas - Tardbp](https://mouse.brain-map.org/gene/show/Tardbp): Mouse brain expression patterns
[BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/search?search_term=TARDBP): Developmental expression data

Pathway Diagram

Mermaid diagram (expand to render)

Disease Mechanism Summary

## Recent Research (2024-2025)

Recent advances in TDP-43 (TARDBP) research have revealed new insights into ALS and FTD pathogenesis:

TDP-43 Aggregation: Mechanisms of TDP-43 proteinopathy in ALS and FTD[^recent1].
Stress Granules: TDP-43 mislocalization and stress granule dynamics[^recent2].
DNA Damage: DNA damage response defects induced by mutant FUS and TDP-43 inclusions[^recent3].
Therapeutic Targets: Novel approaches targeting TDP-43 aggregation[^recent4].

[^recent1]: [TDP-43 aggregation mechanisms in neurodegenerative diseases (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[^recent2]: [Stress granule dynamics and TDP-43 mislocalization in ALS (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/)

[^recent3]: [DNA damage response defects in TDP-43 and FUS proteinopathy (2025)](https://pubmed.ncbi.nlm.nih.gov/40437235/)

[^recent4]: [Novel therapeutic targets for TDP-43 aggregation (2025)](https://pubmed.ncbi.nlm.nih.gov/40345678/)

TDP-43 Pathology Comparison Across Diseases

TDP-43 Post-translational Modifications

Recent Publications (2024-2026)

Recent research on TDP-43 has expanded our understanding of its role in ALS/FTD:

[Seddighi et al., Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38277467/) — Cryptic splicing generates de novo proteins in TDP-43-related ALS/FTD.

[Chatterjee et al., Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/38890531/) — EV tau and TDP-43 as diagnostic biomarkers in FTD and ALS.

[Irwin et al., Fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38278991/) — Biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.

[Garcia-Montojo et al., TDP-43 proteinopathy triggered by loss of ASRGL1 (2024)](https://pubmed.ncbi.nlm.nih.gov/38755145/) — TDP-43 proteinopathy in ALS triggered by loss of ASRGL1.

[Casiriraghi et al., Rapamycin beneficial in ALS patient-derived iPSC models (2025)](https://pubmed.ncbi.nlm.nih.gov/39536963/) — Modeling of TDP-43 proteinopathy identifies rapamycin as beneficial.

[Spence et al., RNA aptamer reveals nuclear TDP-43 pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38443601/) — Nuclear TDP-43 pathology is an early aggregation event.

References

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: TARDBP
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: TARDBP
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: TARDBP

Pathway Diagram

The following diagram shows the key molecular relationships involving TARDBP — TAR DNA Binding Protein 43 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Associated Diseases

Als — associated with

[View disease page](/diseases/als)

ALS — associated with

[View disease page](/diseases/als)

ALS-FTD — associated with

[View disease page](/diseases/als-ftd)

Alzheimer — associated with

[View disease page](/diseases/alzheimer)

ALZHEIMER — associated with

[View disease page](/diseases/alzheimer)

Alzheimer's disease — associated with

[View disease page](/diseases/alzheimers-disease)

Alzheimer'S Disease — associated with

[View disease page](/diseases/alzheimers-disease)

Amyotrophic Lateral Sclerosis — associated with

[View disease page](/diseases/amyotrophic-lateral-sclerosis)

dementia — associated with

[View disease page](/diseases/dementia)

Dementia — associated with

[View disease page](/diseases/dementia)

DEMENTIA — associated with

[View disease page](/diseases/dementia)

frontotemporal — associated with

[View disease page](/diseases/frontotemporal)

frontotemporal dementia — associated with

[View disease page](/diseases/frontotemporal-dementia)

Frontotemporal Dementia — associated with

[View disease page](/diseases/frontotemporal-dementia)

FRONTOTEMPORAL DEMENTIA — associated with

[View disease page](/diseases/frontotemporal-dementia)

Frontotemporal Lobar Degeneration — associated with

[View disease page](/diseases/frontotemporal-lobar-degeneration)

Frontotemporal Lobar Degeneration with TDP-43 Type C — implicated in

[View disease page](/diseases/frontotemporal-lobar-degeneration-with-tdp-43-type-c)

Parkinson — associated with

[View disease page](/diseases/parkinson)

Parkinson's disease — associated with

[View disease page](/diseases/parkinsons-disease)

GWAS Evidence

Genetic associations from the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/) supporting gene-disease relationships:

rs9497975 — HIV-1 control (p = 7.00e-08, n = 2,362 European ancestry cases) [PLoS Genet PMID:20041166](https://pubmed.ncbi.nlm.nih.gov/20041166/)
rs17324272 — (p = 2.00e-07, n = ) [ ](https://www.ebi.ac.uk/gwas/studies/)
rs212388 — Crohn's disease (p = 3.00e-14, n = Up to 12,924 European ancestry cases, up to 21,442 European ancestry controls ) [Nature PMID:23128233](https://pubmed.ncbi.nlm.nih.gov/23128233/)
rs4654925 — Ulcerative colitis (p = 9e-22, n = 1,043 European ancestry cases, 1,703 European ancestry controls) [Nat Genet PMID:20228798](https://pubmed.ncbi.nlm.nih.gov/20228798/)
rs2138852 — Mean platelet volume (p = 7e-28, n = 1,606 European ancestry individuals) [Am J Hum Genet PMID:19110211](https://pubmed.ncbi.nlm.nih.gov/19110211/)
rs12049330 — Major depressive disorder (p = 6.00e-06, n = 1,020 European ancestry cases, 1,636 European ancestry controls) [Mol Psychiatry PMID:20125088](https://pubmed.ncbi.nlm.nih.gov/20125088/)
rs1128334 — Systemic lupus erythematosus (p = 2.00e-11, n = 314 Chinese ancestry cases, 1,484 Chinese ancestry controls) [PLoS Genet PMID:20169177](https://pubmed.ncbi.nlm.nih.gov/20169177/)

📖 View canonical wiki page →

TARDBP — TAR DNA Binding Protein 43

TARDBP (TDP-43)

TARDBP (TDP-43)

Overview

Gene And Protein Architecture

Core Biological Functions

RNA Splicing And Transcriptome Integrity

RNA Transport, Translation, And Stress Response

DNA Damage And Mitochondrial Coupling

Disease Associations

ALS Spectrum

Frontotemporal Dementia And ALS-FTD

Alzheimer Co-Pathology And LATE

Biomarker And Translational Relevance

Therapeutic Strategies

Direct TDP-43 Targeting

Proteostasis And Autophagy Modulation

Trial Design Implications

Research Gaps

See Also

External Links

Brain Atlas Resources

Pathway Diagram

Disease Mechanism Summary

TDP-43 Pathology Comparison Across Diseases

TDP-43 Post-translational Modifications

Recent Publications (2024-2026)

References

Related Hypotheses

Pathway Diagram

Associated Diseases

GWAS Evidence